EUVIMEDEUVIMED entdecken
Open Access

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial

Drei versus 6 Monate adjuvante Oxaliplatin-Fluoropyrimidin-Chemotherapie bei kolorektalem Karzinom: Endergebnisse der SCOT-Studie, einer internationalen randomisierten Phase-III-Nichtunterlegenheitsstudie

Timothy Iveson iD, Mark P Saunders, Caroline Kelly iD, Rachel S Kerr, Jim Cassidy, Niels Henrik Hollander iD, Josep Tabernero iD, Andrew Haydon iD, Bengt Glimelius iD, Andrea Harkin iD, Karen Allan, John McQueen iD und 20 weitere

Journal of Clinical Oncology · 01.03.2026 · 44 (7) · 534-539

DOI: 10.1200/jco-25-00621 ↗

Auf einen Blick

In SCOT war 3 Monate adjuvante Oxaliplatin-Fluoropyrimidin-Chemotherapie beim kolorektalen Karzinom beim Gesamtüberleben nicht unterlegen gegenüber 6 Monaten. Das galt auch für Patient:innen mit Rektumkarzinom.

Fragestellung

Ist 3 Monate im Vergleich zu 6 Monaten adjuvanter Oxaliplatin-Fluoropyrimidin-Chemotherapie beim kolorektalen Karzinom beim Gesamtüberleben nicht unterlegen?

Methode

Internationale randomisierte Phase-III-Nichtunterlegenheitsstudie; 1:1-Zuteilung zu 3 oder 6 Monaten CAPOX oder FOLFOX; medianes Follow-up 113 Monate.

Ergebnisse

5-Jahres-OS jeweils 82,4 %; Hazard Ratio 0,96 (95 %-KI 0,8–1,07); 1.255 OS-Ereignisse. Nichtunterlegenheit von 3 Monaten für OS gezeigt; auch bei 1.087 Patient:innen mit Rektumkarzinom.

Schlussfolgerung der Autor:innen

Die Autor:innen schließen, dass 3 Monate adjuvante Chemotherapie beim OS nicht unterlegen sind und für die meisten Patient:innen empfohlen werden sollten.

Kernaussagen

  • 5-Jahres-OS: 82,4 % in beiden Gruppen
  • Hazard Ratio 0,96 (95 %-KI 0,8–1,07)
  • Nichtunterlegenheit auch bei Rektumkarzinom gezeigt

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2026. Verfasst von Timothy Iveson und 31 weiteren Autor:innen. Beteiligte Einrichtung: University of Southampton, Southampton, United Kingdom. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.

Autor:innen und Institutionen

  • University of Southampton, Southampton, United Kingdom.
  • The Christie Hospital, Manchester, United Kingdom.
  • Glasgow Oncology Clinical Trials Unit, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark.
  • Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, CIBERONC, Barcelona, Spain.

ORCID-Profile: Timothy Iveson, Caroline Kelly, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, John McQueen, Sarah Pearson, Kathleen A Boyd, Louise Medley, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Cunningham, Tamas Hickish, Harpreet S Wasan, David Church, Enric Domingo

Zitieren

APA

Iveson, T., Saunders, M. P., Kelly, C., Kerr, R. S., Cassidy, J., Hollander, N. H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Pearson, S., Boyd, K. A., Briggs, A. H., Waterston, A., Medley, L., Ellis, R., Dhadda, A. S., …, & Domingo, E. (2026). Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial. Journal of Clinical Oncology, 44(7), 534-539. https://doi.org/10.1200/jco-25-00621

Vancouver

Iveson T, Saunders MP, Kelly C, Kerr RS, Cassidy J, Hollander NH, et al. Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial. Journal of Clinical Oncology. 2026;44(7):534-539. doi:10.1200/jco-25-00621

BibTeX
@article{Iveson2026,
  author = {Iveson, Timothy and Saunders, Mark P and Kelly, Caroline and Kerr, Rachel S and Cassidy, Jim and Hollander, Niels Henrik and Tabernero, Josep and Haydon, Andrew and Glimelius, Bengt and Harkin, Andrea and Allan, Karen and McQueen, John and Pearson, Sarah and Boyd, Kathleen A and Briggs, Andrew H and Waterston, Ashita and Medley, Louise and Ellis, Richard and Dhadda, Amandeep S and Harrison, Mark and Falk, Stephen and Rees, Charlotte and Olesen, Rene K and Propper, David and Bridgewater, John and Azzabi, Ashraf and Cunningham, David and Hickish, Tamas and Gollins, Simon and Wasan, Harpreet S and Church, David and Domingo, Enric},
  title = {Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {7},
  pages = {534--539},
  doi = {10.1200/jco-25-00621}
}
Kostenlos starten →